Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced ...

Nigerians suffering from ailments caused by their consumption of sugar-sweetened beverages (SSBs) are spending billions of ...

Rhythm Pharma gets orphan drug designation for its setmelanotide to treat hypothalamic obesity in Japan: Boston Friday, March 21, 2025, 16:00 Hrs [IST] Rhythm Pharmaceuticals, Inc ...

Rhythm Pharmaceuticals received an orphan-drug designation from Japan's Ministry of Health, Labour and Welfare for its treatment for a certain type of obesity.

Rhythm Pharmaceuticals (RYTM) announced it has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for ...

Labour and Welfare (MHLW) for setmelanotide as a treatment for acquired hypothalamic obesity. Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity.

Lack of turnout and a dearth of owners with appropriate experience are among the drivers of the current equine welfare crisis ...

Having lost a great deal of weight appears to offer some protection against ill health even for those who have regained some ...

Rajya Sabha member Milind Murli Deora on Tuesday urged the government to levy higher taxes on high sugar and fat food products that cause obesity and ban their advertisements targeting children.